Claritev Corporation
Claritev Corporation (CTEV) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctev · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Claritev Corporation (CTEV) measures how much investors pay for each dollar of the company's trailing earnings. CTEV's current PE ratio of N/A is calculated by dividing its stock price of $26.78 by its TTM earnings per share of -$17.16.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%22.2x
MedianQ3 · 75%82.7x
Max
At N/A, CTEV's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Healthcare Information Services · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Claritev CorporationYou CTEV | $457M | N/A | — | -$17.16 |
 AxoGen, Inc. AXGN | $2.2B | N/A | — | -$0.34 |
 Dianthus Therapeutics, Inc. DNTH | $3.4B | N/A | — | -$4.30 |
 Evolent Health, Inc. EVH | $542M | N/A | — | -$4.68 |
 GoodRx Holdings, Inc. GDRX | $927M | 31.72x | +51.6% | $0.09 |
 Integra LifeSciences Holdings Corporation IART | $1.3B | N/A | — | -$6.73 |
 InMode Ltd. INMD | $825M | 10.12x | -51.6% | $1.45 |
Industry Average 2 peers with valid PE | — | 20.92x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-17.30 | — | |
2024-12-31 FY2024 | — | $-101.92 | — | |
2023-12-31 FY2023 | — | $-5.69 | — | |
2022-12-31 FY2022 | — | $-35.87 | — | |
2021-12-31 FY2021 | 4.66x | $6.27 | — | |
2020-12-31 FY2020 | — | $-44.23 | — | |
2019-12-31 FY2019 | 82.70x | $0.35 | +273.0% | |
2018-12-31 FY2018 | 22.17x | $1.32 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Claritev Corporation (CTEV) measures how much investors pay for each dollar of the company's trailing earnings. CTEV's current PE ratio of N/A is calculated by dividing its stock price of $26.78 by its TTM earnings per share of -$17.16.
Frequently asked questions
CTEV pe ratio · 6 questionsCTEV's current PE ratio is N/A as of 2026-06-08, based on a stock price of $26.78 and TTM EPS of -$17.16. Data sourced from Financial Modeling Prep via CTEV's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Claritev Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08